MLTX

SEC filing MLTX Enters $0 Master Commercial Supply Agreement with Vetter Pharma, Secures Manufacturing Capacity for Sonelokimab

1d ago

News Nasdaq Jumps 150 Points; US Pending Home Sales Rise

14d ago

News 12 Health Care Stocks Moving In Monday's Intraday Session

14d ago

News MoonLake Immunotherapeutics Stock Plummets After Phase 3 Data Readouts

14d ago

News Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery

14d ago

Insider trade Sale by Matthias Bodenstedt (Chief Financial Officer)

19d ago

News MoonLake Immunotherapeutics GAAP EPS of -$0.98 misses by $0.07

22d ago

Insider trade Sale by Matthias Bodenstedt (Chief Financial Officer)

46d ago

Insider trade Sale by da Silva Jorge Santos (Chief Executive Officer)

48d ago

Insider trade Sale by Matthias Bodenstedt (Chief Financial Officer)

52d ago

News MoonLake upgraded at Rothschild & Co Redburn citing potential FDA nod for lead drug

75d ago

News US Premarket Movers: Arcellx, Domino’s, MoonLake, Vanda, Veris

99d ago

News MoonLake Finds Its Footing as FDA Wins Reset the Risk-Reward Profile

118d ago

News MoonLake cut to sell at Goldman Sachs on risks to lead asset’s approval

138d ago

News MoonLake surges as no additional studies are required for lead drug

145d ago

News MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

153d ago

News MoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm’s Investigation

153d ago

News MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman

153d ago

News MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm

153d ago

News MLTX Investor News: If You Have Suffered Losses in MoonLake Immunotherapeutics (NASDAQ: MLTX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

153d ago

News MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman

153d ago

News Securities Fraud Investigation Into MoonLake Immunotherapeutics (MLTX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

153d ago

News ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – MLTX

153d ago

News MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

153d ago

News ROSEN, LEADING TRIAL ATTORNEYS, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – MLTX

153d ago